Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonlicromanol in Adult Subjects With a Genetically Confirmed Mitochondrial DNA tRNALeu(UUR) m.3243A>G Variant (KHENERFIN)
NCT06451757Phase 3Recruiting
- Sponsor
- Khondrion
- Start
- Apr 2026
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of sonlicromanol in mitochondrial disease, maternally inherited diabetes and deafness (MIDD), Mitochondrial encephalomyopathy (ME), sponsored by Khondrion. Started Apr 2026; status: recruiting.
02
Drugs
sonlicromanol
03
Conditions
mitochondrial diseasematernally inherited diabetes and deafness (MIDD)Mitochondrial encephalomyopathy (ME)
Beyond the preview
Go deeper on NCT06451757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06451757.